On March 27, Cansino Biologics Inc(688185) ( Cansino Biologics Inc(688185) ) released the annual report of 2021. During the period, the company achieved an operating revenue of 4.3 billion yuan, a year-on-year increase of 1717482%; Net profit of 1.914 billion yuan; Deduct non net profit of 1.797 billion yuan, reversing losses year-on-year.
From the perspective of income composition, Cansino Biologics Inc(688185) ‘s overseas income accounts for the main body. In 2021, the domestic revenue of the company was 1.242 billion yuan and the overseas revenue was 3.057 billion yuan. The gross profit margin of domestic business is 58.6%, and that of overseas business is 74.4%.
Cansino Biologics Inc(688185) said that the increase in revenue and profit was mainly due to the conditional listing approval and emergency use authorization of the company’s recombinant covid-19 virus vaccine (adenovirus type 5 vector) from many countries at home and abroad. The commercialization of the product had a positive impact on the company’s total operating revenue and profit indicators.
Cansino Biologics Inc(688185) mainly engaged in R & D, production and commercialization of innovative vaccines. The company’s product pipeline includes 17 innovative vaccine products for the prevention of Ebola virus disease, meningitis, COVID-19 pneumonia, pneumonia, DPT, tuberculosis, herpes zoster and 12 indications.
The announcement shows that by the end of 2021, Cansino Biologics Inc(688185) of recombinant covid-19 pneumonia vaccine for inhalation has completed phase I / II clinical trials, except that covid-19 vaccine has been listed in some countries; Ebola virus vaccine products have obtained new drug certificate and production number. Products such as DPT combined vaccine, polio vaccine and herpes zoster vaccine are still under preclinical research.
From the perspective of R & D, Cansino Biologics Inc(688185) said that at present, the company’s vaccine R & D project is continuously promoting, several innovative vaccines are in the stage of clinical trial and research, and R & D expenditure continues to increase. In 2021, Cansino Biologics Inc(688185) R & D expenses reached 879 million yuan, an increase of 105% over the same period of last year. The number of R & D personnel of the company increased from 219 in 2020 to 309.
Among them, covid-19 vaccine is still the focus of the company’s R & D investment. In 2021, the company invested more than 650 million yuan in covid-19 vaccine and covid-19 vaccine for inhalation, with a cumulative investment of more than 900 million yuan.
Cansino Biologics Inc(688185) said that the company’s covid-19 vaccine products have been vaccinated nationwide and approved for sequential booster immunization; At the same time, the company has cooperated with local governments in many developing countries to build overseas filling production lines, realizing from vaccine clinical trials to localized production; In 2021, two kinds of meningococcal conjugate vaccines newly obtained the drug registration certificate are also gradually promoting the access work in various provinces. The company is gradually moving forward from R & D-oriented enterprise to industrialization and commercialization.
Since the net profit attributable to the parent company and the net profit deducted from non net profit of the company in 2021 are positive, which is in line with the situation of “the unprofitable company achieved profit for the first time at the time of listing”, the special logo of the company’s A-share abbreviation will be cancelled on March 29, changed from ” Cansino Biologics Inc(688185) -u” to ” Cansino Biologics Inc(688185) “, and the A-share ticket code will remain unchanged.
On the evening of March 27, according to the profit distribution plan announced simultaneously, Cansino Biologics Inc(688185) plans to distribute a cash dividend of 8 yuan (including tax) for every 10 shares to all shareholders of the company, and does not convert the capital reserve into share capital or bonus shares.
Cansino Biologics Inc(688185) said that the company is in the stage of accelerating upgrading, expansion and development, and needs to invest a lot of money in product R & D and industrialization construction, so as to continuously improve the company’s technical strength and core competitiveness. At the same time, the company needs to retain a certain proportion of funds to ensure the smooth implementation of strategic planning and the unpredictability of the market.
